Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects with Cystic Fibrosis
2017-000797-11Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of elexacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Primary endpoints (Parts D and E). Started May 2017; status: completed.
02
Drugs
elexacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2017-000797-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000797-11.